QUOTE AND NEWS
Benzinga  Jun 28  Comment 
Deutsche Bank upgraded shares of Bio-Rad Laboratories, Inc. (NYSE: BIO), as it sees light at the end of the tunnel, given the company's ability to accelerate sales growth and expand margins. Investments To Bear Fruit Analyst Dan Leonard...
Benzinga  Apr 27  Comment 
Keith Meister, founder of Corvex Management, was interviewed by CNBC's David Faber at the 13D Monitor's 8th annual Active-Passive Investor Summit. Meister said he will be presenting a case-story on how an activist investor can collaborate with a...




 
TOP CONTRIBUTORS

Bio-Rad Laboratories (NYSE:BIO) manufactures, develops, and markets laboratory and medical testing instruments through its two major arms, Clinical Diagnostics and Life Sciences. Bio-Rad's products in the Clinical Diagnostics division include instruments for diagnosing diabetes as well as testing for blood-based and genetic disorders. The Life Sciences division includes instruments used for research in functional genomics, proteomics, and food safety.

As a manufacturer of instruments for laboratory testing and research, Bio-Rad is dependent on government funding for scientific research. Its business model benefits, however, from recurring revenue that it earns from sale of the testing ingredients that are consumed with each test that a customer performs on Bio-Rad's instruments. Recurring revenue from consumable ingredients for the diverse array of testing instruments that Bio-Rad sells will help the consistency of the company's revenue over the years.

That's 2 clveer by half and 2x2 clever 4 me. Thanks!

Business Growth

FY 2010 (ended December 31, 2010[1]

  • Net revenue increased 8% to $1.93 billion.
  • Net income increased 28% to $185.5 million.

In 2010, revenue growth was driven by organic growth in the Clinical Diagnostics and Life Sciences divisions as well as added revenue from Bio-Rad's acquisition of Biotest in January of 2010[2]. The added revenue from Biotest accounted for approximately 40% of Bio-Rad's growth for the year, while strong growth in the Clinical Diagnostics division was driven by sales for blood typing, quality control testing, and the BioPlex 2200 product line.[3]

Trends and Forces

Bio-Rad Benefits from Recurring Revenue from the Sale of Consumables for its Products

In addition to manufacturing and selling instruments for laboratory testing and research, Bio-Rad sells the testing ingredients that are consumed with each test performed on these instruments.[4] This sale of consumable testing ingredients provides Bio-Rad with a steady and recurring revenue stream that can drive consistent revenue growth. Bio-Rad's ability to sell consumables along with its instruments also heightens the focus on market adoption for its relatively new products, such as its BioPlex 2000, for which it is working on increasing market share. The more customers that Bio-Rad can get to adopt its new instruments, the greater its recurring revenue stream from consumables of that instrument will be.

Life Sciences Revenue Growth is Dependent on Government Funded Research

Sales in the Life Sciences division have lagged in Europe and Japan due to the weak economic situations in those countries leading to decreased government funded research.[5] While revenues in the US market have not been hit as hard due to the lagging economy, the suppressed revenue in the European and Japanese markets illustrate the dependence of Bio-Rad's Life Sciences products on government funded research. As governments world-wide change their attitudes toward funding basic science research, particularly in genetics, Bio-Rads revenue will be impacted.

Competition

Bio-Rad competes with several laboratory testing and research companies, including Life Technologies Corp (LIFE), Abbott Laboratories (ABT), Siemens AG (SI), and Thermo Fisher Scientific (TMO).

References

  1. Bio-Rad Reports Record Fourth-Quarter and Full-Year 2010 Financial Results
  2. Bio-Rad Completes the Purchase of Certain Diagnostics Businesses of Biotest AG
  3. Bio 2010 10K
  4. Bio-Rad Consumable Products
  5. Bio-Rad's Q3 Revenues Increase 2 Percent amid 'Weak' Markets
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki